Michael Danso, MD
Hematology & Oncology · Norfolk, VANPI 1467445999
Payments from drug & device makers
Across 1,465 payments — averaging $4739.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2.5M
- Genentech, Inc.$1.3M
- Merck$1.2M
- Eli Lilly$475K
- Novartis$351K
- Jazz Pharmaceuticals Inc.$349K
- plus $750K from 28 others
Across 10 payments — averaging $1379.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$13K
- Novartis$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $2,548,987 |
| Genentech, Inc. | 351 | $1,296,353 |
| Merck | 520 | $1,174,024 |
| Eli Lilly | 30 | $475,023 |
| Novartis | 25 | $351,126 |
| Jazz Pharmaceuticals Inc. | 142 | $348,515 |
| Pfizer | 160 | $230,108 |
| Janssen Research & Development, LLC | 10 | $115,116 |
| G1 Therapeutics, Inc. | 25 | $84,483 |
| GSK | 22 | $68,196 |
| Medivation LLC. | 2 | $44,420 |
| Biontech SE | 17 | $42,166 |
| Veru Inc. | 9 | $33,491 |
| Gilead | 19 | $32,317 |
| Astrazeneca UK Limited | 6 | $30,522 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25,625 |
| F. Hoffmann-la Roche AG | 5 | $19,155 |
| Viiv Healthcare Company | 3 | $9,523 |
| EMD Serono, Inc. | 5 | $4,632 |
| Seagen Inc. | 4 | $4,505 |
| Genentech USA, Inc. | 6 | $1,981 |
| Immunomedics, Inc. | 2 | $940 |
| Adaptive Biotechnologies Corporation | 2 | $800 |
| Daiichi Sankyo Inc. | 5 | $500 |
| Puma Biotechnology, Inc. | 5 | $371 |
| Stemline Therapeutics Inc. | 2 | $204 |
| Array Biopharma Inc | 1 | $150 |
| Amgen | 1 | $125 |
| Sanofi | 1 | $125 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Verastem, Inc. | 1 | $114 |
| AbbVie | 1 | $107 |
| Mckesson Corporation | 1 | $28 |
| Bayer | 1 | $14 |
How this compares
$6,943,870 in reported general payments places this provider in the 95th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Norfolk
- Nina BalanchivadzeNorfolk$877K
- Gary SimmonsNorfolk$710K
- Boon KokNorfolk$304K
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.